Recruiting Lung Cancer Studies in Gainesville
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy...
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy ...
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Vo...
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemothera...
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS)....
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer...
About Lung Cancer Clinical Trials in Gainesville
Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.
There are currently 6 lung cancer clinical trials recruiting participants in Gainesville, FL. These studies are seeking a combined 3,855 participants. Research is being sponsored by AstraZeneca, Mirati Therapeutics Inc., Amgen and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lung Cancer Clinical Trials in Gainesville — FAQ
Are there lung cancer clinical trials in Gainesville?
Yes, there are 6 lung cancer clinical trials currently recruiting in Gainesville, FL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Gainesville?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Gainesville research site will contact you about next steps.
Are clinical trials in Gainesville free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Gainesville studies also compensate for your time and travel.
What lung cancer treatments are being tested?
The 6 active trials in Gainesville are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.
Data updated March 2, 2026 from ClinicalTrials.gov